FDA Approves Its First ‘Clocked’ ANDA
This article was originally published in The Pink Sheet Daily
Application for an acne medication is first to be approved with a formal review goal under GDUFA, and comes five months early.
You may also be interested in...
The requirements to join the new real-time review pilot program strongly resemble those of the breakthrough designation, which could come as an unpleasant surprise for some sponsors.
System likely will evolve as post-pandemic world unfolds, but adds to list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.